Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09IGF
|
||||
Former ID |
DIB011691
|
||||
Drug Name |
MG-28
|
||||
Synonyms |
FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [543659] | ||
Company |
Institut Catala d'Oncologia
|
||||
Target and Pathway | |||||
Target(s) | Fatty acid synthase | Target Info | Inhibitor | [543659] | |
Pathway Interaction Database | p73 transcription factor network | ||||
Validated transcriptional targets of deltaNp63 isoforms | |||||
PathWhiz Pathway | Fatty Acid Biosynthesis | ||||
WikiPathways | Fatty Acid Biosynthesis | ||||
Nuclear Receptors Meta-Pathway | |||||
Liver X Receptor Pathway | |||||
Activation of Gene Expression by SREBP (SREBF) | |||||
SREBF and miR33 in cholesterol and lipid homeostasis | |||||
SREBP signalling | |||||
Metabolism of water-soluble vitamins and cofactors | |||||
Integration of energy metabolism | |||||
Fatty acid, triacylglycerol, and ketone body metabolism | |||||
AMPK Signaling | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.